EDQM conducts GMP inspection at Biocon’s Bangalore unit

07 Oct 2022 Evaluate

European Directorate for the Quality of Medicines & HealthCare (EDQM) has conducted a GMP inspection of an API manufacturing site of Biocon’s unit in Bangalore from September 12 to 14, 2022 and issued a list of deficiencies on October 05, 2022. There were no critical deficiencies and one deficiency cited under the category ‘Major’. The company will be responding to the agency with appropriate corrective and preventive actions within the stipulated time. The company remains committed to the Quality, Safety & Efficacy of its products.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

366.40 -6.25 (-1.68%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×